SinoMab BioScience EV/EBITDA
Что обозначает EV/EBITDA в SinoMab BioScience?
EV/EBITDA SinoMab BioScience Limited является N/A
Какое определение для EV/EBITDA?
EV / EBITDA - это стоимость предприятия, деленная на прибыль до вычета процентов, налогов, обесценивания и амортизации. При помощи неё измеряется, насколько дорогой является акция, и она более действительна для сравнения компаний, чем для соотношения цены и прибыли. Она измеряет цену (в форме стоимости предприятия), которую инвестор платит в пользу денежного потока компании (в форме EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA компаний в Health Care сектор на HKSE по сравнению с SinoMab BioScience
Что делает SinoMab BioScience?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Компании с ev/ebitda похож на SinoMab BioScience
- Novavax имеет EV/EBITDA из N/A
- Cazaly Resources имеет EV/EBITDA из N/A
- DC Acquisition имеет EV/EBITDA из N/A
- Macarthur Minerals имеет EV/EBITDA из N/A
- Sierra Madre Gold and Silver имеет EV/EBITDA из N/A
- Rathdowney Resources имеет EV/EBITDA из N/A
- SinoMab BioScience имеет EV/EBITDA из N/A
- Big Dougie Capital имеет EV/EBITDA из N/A
- Income Trust имеет EV/EBITDA из N/A
- Aloro Mining имеет EV/EBITDA из N/A
- Manganese X имеет EV/EBITDA из N/A
- Coho Collective Kitchens имеет EV/EBITDA из N/A
- Viva Gold имеет EV/EBITDA из N/A